Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects
NCT ID: NCT03138356
Last Updated: 2017-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
126 participants
INTERVENTIONAL
2017-05-25
2017-11-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will comprise:
* A Screening period of maximum 28 days;
* Three treatment periods during which subjects will be resident in the Unit from the day before dosing with the IMP (Day -1) until at least 72 hours after dosing; discharged on the morning of Day 4; and
* A final Follow-up Visit within 5 to 7 days after the last administration of the IMP.
There will be a minimum washout period of 7 to 14 days between each dose administration
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1 Treatment A
Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR (Extended-release) FDC (Fixed-dose combination) tablet administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA).
2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet
Used in Treatment A and Treatment D.
Cohort 1 Treatment B
Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA).
2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet
Used in Treatment B and Treatment E.
Cohort 1 Treatment C (Reference product)
Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin XR) co-administered under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA).
2.5 mg ONGLYZA® (saxagliptin) tablet
Used in treatments C and F.
5 mg Forxiga® (dapagliflozin) tablet
Used in treatments C, F and I.
500 mg Glucophage XR®
Used in treatments C, F and I.
Cohort 2 Treatment D
Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state
The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED).
2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet
Used in Treatment A and Treatment D.
Cohort 2 Treatment E
Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED).
2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet
Used in Treatment B and Treatment E.
Cohort 2 Treatment F (Reference Product)
Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED).
2.5 mg ONGLYZA® (saxagliptin) tablet
Used in treatments C and F.
5 mg Forxiga® (dapagliflozin) tablet
Used in treatments C, F and I.
500 mg Glucophage XR®
Used in treatments C, F and I.
Cohort 3 Treatment G
Single-dose dapagliflozin (5 mg) / metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH).
5 mg dapagliflozin / 1000 mg metformin XR FDC
Used in Treatment G.
Cohort 3 Treatment H
Single-dose dapagliflozin (5 mg) / metformin (850 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH).
5 mg dapagliflozin / 850 mg metformin XR FDC
Used in Treatment H.
Cohort 3 Treatment I (Reference Product)
Single-dose Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH).
5 mg Forxiga® (dapagliflozin) tablet
Used in treatments C, F and I.
500 mg Glucophage XR®
Used in treatments C, F and I.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet
Used in Treatment B and Treatment E.
2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet
Used in Treatment A and Treatment D.
5 mg dapagliflozin / 850 mg metformin XR FDC
Used in Treatment H.
5 mg dapagliflozin / 1000 mg metformin XR FDC
Used in Treatment G.
2.5 mg ONGLYZA® (saxagliptin) tablet
Used in treatments C and F.
5 mg Forxiga® (dapagliflozin) tablet
Used in treatments C, F and I.
500 mg Glucophage XR®
Used in treatments C, F and I.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Provision of signed and dated, written informed consent prior to any study specific procedures.
2. Healthy male and/or female subjects aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture.
3. Female subject must either:
3.1. Be of non-childbearing potential:
* Must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) at Screening and negative urine pregnancy test within 24 hours prior to first IMP administration.
* Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation. 3.2. Or, if of childbearing potential:
* Must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) at Screening and within 24 hours prior to first IMP administration.
* Must not be nursing (breastfeeding).
* If heterosexually active, agree to consistently use a highly effective method of contraception to avoid pregnancy, from at least 4 weeks prior to dosing and throughout the study and for up to 90 days after the last dose of IMP. 4. Sexually active fertile male subjects must use effective birth control for the entire study and 90 days after the last dose of IMP if their partners are women of childbearing potential. 5. Have a body mass index (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
Exclusion Criteria
2. Current or recent (within 3 months of first IMP dosing) gastrointestinal disease that may impact drug absorption and affect the PK of the study drugs. Additionally, any gastrointestinal surgery (e.g., partial gastrectomy, pyloroplasty) including cholecystectomy that may impact drug absorption.
3. Any major surgery, as determined by the investigator, within 4 weeks of first IMP dosing.
4. Donation of \> 400 mL of blood within 8 weeks or donation of plasma (except at the Screening Visit) within 4 weeks of first IMP dosing.
5. Blood transfusion within 4 weeks of first IMP dosing.
6. Inability to tolerate oral medication.
7. Inability to tolerate venipuncture or inadequate venous access as determined by the investigator.
8. Recent (within 6 months of first IMP dosing) drug or alcohol abuse as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), Diagnostic Criteria for Drug and Alcohol Abuse.
9. Subjects who drink more than 3 cups of coffee or other caffeinecontaining products a day, or 5 cups of tea a day.
10. Use of tobacco-containing or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to first check-in (Day -1, Treatment Period 1), or a positive nicotine test (i.e., cotinine) at Screening and/or check-in.
11. History of diabetes mellitus.
12. History of heart failure.
13. History of chronic or recurrent urinary tract infection (defined as 3 occurrences per year)
14. Recent vulvovaginal mycotic infection (within 2 months prior to first IMP dosing).
15. Any other sound medical, psychiatric and/or social reason as determined by the investigator.
16. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of Screening.
17. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
18. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest. Note: subjects consented and screened, but not randomized in this study or a previous Phase1 study, are not excluded.
19. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to saxagliptin, dapagliflozin and metformin.
20. Positive screen for drugs of abuse or cotinine at Screening or on first admission to the study center or positive screen for alcohol on first admission to the study center
21. Use of saxagliptin, dapagliflozin and/or metformin within 3 months prior to the first administration of IMP.
22. Use of any prescription drugs or OTC acid controllers within 4 weeks prior to the first administration of IMP except medication cleared by the medical monitor.
23. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
24. Use of any prescribed or non-prescribed medication including analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life. Note: Hormonal replacement therapy is not allowed.
25. Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives.
26. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pablo ForteSoto, MD, MSc, PhD
Role: PRINCIPAL_INVESTIGATOR
PAREXEL Early Phase Clinical Unit London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Harrow, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D168AC00002
Identifier Type: -
Identifier Source: org_study_id